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ABSTRACT
Introduction HIV prevalence among criminal justice 
(CJ)- involved adults is five times higher than the general 
population. Following incarceration, CJ- involved individuals 
experience multilevel barriers to HIV prevention. Pre- 
exposure prophylaxis (PrEP) is a widely available, daily 
medication efficacious in preventing HIV. Little is known 
about PrEP knowledge, acceptability, initiation and 
sustained use among CJ- involved persons or about how 
these outcomes vary by multilevel factors. The Southern 
Pre- Exposure Prophylaxis Study (SPECS) will investigate 
barriers and facilitators for PrEP initiation and sustained 
use among CJ- involved adults, building a foundation for 
PrEP interventions for this underserved population.
Methods and analysis SPECS uses a mixed- methods 
sequential design, including a multisite, prospective cohort 
study in three southern states—North Carolina, Florida 
and Kentucky—and subsequent qualitative interviews. 
HIV- negative adults clinically indicated for PrEP with CJ- 
involvement in the past year (n=660; 220 per site)—will 
be recruited for four quantitative interviews separated 
by 6 months, with 18 months of follow- up. Interviews 
will measure CJ involvement, substance use, sexual 
behaviours, PrEP acceptability and use, healthcare access 
and utilisation, support systems and psychological and 
emotional well- being. We will estimate probabilities of 
PrEP acceptability and use in a CJ- involved population 
using descriptive and multivariable analyses. After the 
follow- up, a subsample that never initiated PrEP, initiated 
but did not sustain PrEP or sustained PrEP will be asked 
to participate in a qualitative interview to contextualise 
their experiences and decisions around PrEP. An inductive 
approach will guide qualitative analyses.
Ethics and dissemination PrEP initiation and sustained 
use rates are unknown among CJ- involved adults. This 
research will identify individual, social and structural 
factors that predict PrEP initiation and use. Data generated 
from the study have the potential to guide research and 
the development and tailoring of PrEP interventions to 
CJ- involved populations and provide context to HIV- related 
outcomes for those with CJ experiences.
INTRODUCTION
In the USA, 1 in every 38 adults is actively 
involved in the criminal justice (CJ) system.1 
Of the 6.6 million CJ- involved adults, over 
two- thirds or 4.5 million, are under a form 
of community- based supervision such as 
probation or parole.1 While incarceration 
rates for white Americans is increasing, the 
CJ system continues to disproportionally 
affect persons of colour (POC). In particular, 
black and Latinx adults are significantly over- 
represented in incarcerated populations. 
Although they represent 12% and 16% of 
the adult population in the USA, respectively, 
black and Latinx Americans make up 33% 
Strengths and limitations of this study
 ► This is the first pre- exposure prophylaxis (PrEP)- 
related multisite, observational cohort among a 
criminal justice (CJ)- involved population, which is 
important as rates of PrEP initiation and sustained 
use remain unknown among those with recent CJ 
experience.
 ► This study will collect longitudinal data relevant to 
the individual, social and structural level for CJ- 
involved populations and will include HIV risk pro-
files typically excluded from studies on CJ- involved 
populations, including men who have sex with men.
 ► We are focused on populations in the southern USA, 
which sit at the intersection of a number of HIV risk 
factors and have received less attention than other 
regions of the USA.
 ► We are relying primarily on self- reported PrEP ini-
tiation and sustained use, which are susceptible to 
recall bias.
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and 23% of the adult prison population.2 3 Racial dispar-
ities in incarceration rates are stark among young black 
men aged 18–19, who are 12 times more likely to experi-
ence incarceration than their white peers.3
Vulnerable populations, such as those experiencing 
poverty, homelessness, severe and persistent mental illness 
or substance use disorders, are frequently trapped by the 
revolving doors of the CJ system and experience multiple 
periods of incarceration in their lifetime.4–6 Increasingly, 
as a consequence of the opioid epidemic, there is a strong 
relationship between the intensity of opioid use and 
history of CJ involvement among people who inject drugs 
(PWIDs).7 Therefore, it is unsurprising that the American 
South, which sees a confluence of racial discrimination, 
poverty and disenfranchisement, has incarceration rates 
among the highest in the nation.8–10 Notably, we also see 
the disparities in mass incarceration reflected in risks of 
HIV transmission. There is a high concentration of those 
with—or at risk of—HIV infection concentrated in the 
US correctional system.
HIV prevalence among CJ- involved adults is five times 
that of the general population, and an estimated one in 
seven individuals infected with HIV pass through the CJ 
system each year.11 12 While incarcerated, CJ- involved indi-
viduals are at risk of coming in contact with HIV through 
unsterile needle practices, tattooing and condomless sex. 
Following periods of incarceration, individuals may also 
rapidly re- engage with risky behaviour that increases the 
risk of transmission, including injection drug use and 
condomless sex, making periods following incarceration 
high risk for community- based HIV transmission.13–15 In 
the American South, where, like incarceration, HIV prev-
alence is among the highest in the USA, black Americans 
account for 54% of new HIV diagnoses.16 It is clear that 
the collateral effects of incarceration on HIV risk among 
POC, including creating and perpetuating imbalanced 
gender ratios in communities due to the dispropor-
tionate incarceration of Black men and thus facilitating 
partnership concurrency, and disrupting access to health-
care, contribute to disproportionally high rates of HIV 
among this population.11 14 17–19 As identified in a 2016 
report from the Centers for Disease Control and Preven-
tion (CDC), the South’s high rates of opioid use, HIV 
stigma, poverty levels, and poor healthcare infrastructure 
have created a perfect storm for an HIV outbreak.16 In 
particular, HIV stigma in the South around sexual orien-
tation, substance use, poverty and sex work limits people 
disclosing their HIV status, adhering to antiretroviral 
medications and seeking healthcare.9 20 Despite this, HIV 
prevention efforts thus far, including interventions to link 
people to HIV care postrelease and risk reduction inter-
ventions, have led to little meaningful change in reducing 
rates of infection in CJ- involved persons in the South.
The failure of traditional approaches (eg, promoting 
HIV testing and the use of condoms) to address 
expanding risk of HIV infections among people most at 
risk has led to new HIV prevention strategies that combine 
behavioural and biomedical approaches. In addition to 
early diagnosis and sustained treatment of HIV infection, 
daily preventative treatment—pre- exposure prophylaxis 
(PrEP) emtricitabine/tenofovir (FTC/TDF)—has been 
credited with recent reductions in rates of new HIV diag-
noses in the USA.21 Efficacy of PrEP has been established 
in randomised control trials and open label studies and 
is approved by the FDA for HIV prevention.22 23 PrEP has 
been recommended by the CDC for any at- risk popu-
lation, including men who have sex with men (MSM), 
PWIDs and heterosexuals who engage in condomless sex 
with at risk populations. The PrEP care cascade includes 
identifying those at highest risk for HIV, increasing HIV 
and PrEP awareness among those individuals, initiating 
PrEP, and retaining individuals in PrEP care.24
Despite its efficacy, PrEP uptake has been slow. It is 
estimated that 1.1 million Americans are candidates for 
PrEP—those engaging in high risk sex or unsafe injection 
drug use—yet, current reports indicate that as few as 7% 
of PrEP candidates have been prescribed PrEP.25 26 Little 
is known about PrEP use among those on post- release 
supervision/parole and probation, and challenges to 
PrEP use among these populations is abundant. To be 
most efficacious, oral PrEP must be taken daily. Addition-
ally, as a prescribed medication, PrEP must be offered to 
candidates in a clinical setting, followed by regular moni-
toring for adverse effects, sustained use and sexually trans-
mitted infections (STIs) including HIV. Procurement of 
PrEP also requires navigating systems to cover the cost of 
the medication and attendant testing. A major additional 
challenge is an under appreciation of HIV acquisition risk 
among those who the WHO consider to be at substantive 
risk. Substantive risk is defined as individuals belonging 
to a group that has a disproportionate burden of HIV, 
which includes CJ populations.27 Therefore, despite its 
promise, PrEP is underutilised and understudied in one 
of the most at- risk populations in the US—individuals 
with recent CJ involvement.
Objectives
This paper describes The Southern Pre- Exposure 
Prophylaxis Study (SPECS), which uses a mixed- methods 
sequential design. SPEC includes a prospective obser-
vational cohort study, followed by qualitative interviews 
which are designed to respond to and close the knowl-
edge gap regarding PrEP and those involved in the CJ 
system. SPECS is a multisite, 5- year study that will take 
place in three, diverse southern settings: North Carolina, 
Kentucky, and Florida. The specific aims of this study 
are to: (1) characterise PrEP knowledge and accept-
ability among those placed on postrelease supervision/
parole or probation within the last 12 months, (2) iden-
tify the multilevel factors that predict PrEP initiation and 
sustained use among those placed on post- release super-
vision/parole or probation within the last 12 months and 
(3) qualitatively assess the multilevel factors that affect 
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Broad goals for the study
The significance of the study is punctuated by the 
confluence of the continuing dual epidemics of incar-
ceration and HIV. Very few studies have examined knowl-
edge, acceptability, initiation and sustained use of PrEP 
among individuals with CJ involvement. Importantly, 
the proposed investigations will identify the multilevel 
barriers and facilitators that predict PrEP initiation and 
sustained use among parolees and probationers, building 
the foundation for next- step PrEP interventions for this 
largely underserved population.
Conceptual framework
Both the socioecological model and the National Insti-
tute of Minority Health and Health Disparpities research 
framework inform SPECS,28 29 centralising the impor-
tance of health disparities that span multilevel domains of 
influence. Specifically, these domains extend beyond the 
individual to consider the importance of social and struc-
tural factors and their responsibility for reducing health 
inequalities.28 29 These frameworks will be used in combi-
nation to observe and study the longitudinal patterns 
of PrEP initiation and sustained use among people on 
probation and parole, who are disproproportionately 
POC and experience health disparities (figure 1).
METHODS AND ANALYSES
Study design
This study is a prospective longitudinal cohort of indi-
viduals with CJ involvement and a clinical indication for 
PrEP in North Carolina, Florida and Kentucky.
Participants
Participants will be HIV negative adults over the age of 
18 who were placed on postrelease supervision/parole or 
probation within the last 12 months. Eligible participants 
will be at substantial risk for HIV infection based on CDC/
WHO criteria for PrEP eligibility: PWIDs, persons with 
recent bacterial STI diagnosis, and/or individuals who 
are at a higher risk for being exposed to HIV through sex, 
including MSM and those with infrequent condom use.
Recruitment
Participants will be recruited at three study sites with the 
following enrolment goals: NC (n=220), KY (n=220) and 
FL (n=220). Recruitment will occur at local probation 
and parole offices in Durham and Raleigh, NC, Miami, FL 
and Lexington, KY. Study team members will approach 
individuals in the waiting room at each local probation 
and parole office, and screen in a private on- site room. 
Participants will provide written informed consent. Partic-
ipants may understandably feel uncomfortable answering 
questions about sensitive subjects like sexual activity and 
substance use while at a probation and parole office. They 
will be provided with the option of completing prescreen 
surveys over the phone or at an off- site venue, such as the 
university or study community office.
Quantitative data collection
Standard study assessments will be conducted at base-
line, 6 months, 12 months and 18 months, using Research 
Electronic Data Capture programmed surveys. At all 
timepoints, participants will answer questions related 
to the three domains in the social ecological model of 
PrEP use,25 26 including items on individual level factors 
(ie, sociodemographic information; CJ involvement; 
substance use; sexual risk behaviour; PrEP acceptability, 
initiation, and sustained use; medical comorbidities; 
healthcare utilisation), social level factors (eg, stigma and 
discrimination; social support30 31) and structural level 
factors (healthcare access; housing access; employment; 
public transportation). Participants will also be tested for 
HIV at baseline and at the end of the study at 18- month 
follow- up with an OraQUICK ADVANCE Rapid HIV-1/2 
test. When HIV tests are administered at baseline and 
18 months, participants will also receive pretest, post- 
test and PrEP counselling. All participants that receive a 
positive HIV test will receive support to access HIV care; 
however, those that receive a positive HIV test at baseline 
are ineligible for study enrolment. At baseline, partici-
pants will complete a locator form for which information 
will be updated during phone calls at 3 months, 9 months 
and 15 months. This form contains contact information 
for the participant (eg, phone numbers, address, social 
media handles) as well as for key family or friends. Partic-
ipants will receive US$40 per interview and US$10 per 
phone call. Participants completing all interviews and 
phone calls will receive US$190.
Retention and attrition
We recognise that CJ- involved populations are difficult 
to retain in longitudinal studies (ie, due to recidivism, 
substance use, unstable housing), but our research team 
has been successful in limiting study attrition among 
Figure 1 The social ecological model of PreP use. CJ, 
criminal justice; PrEP, pre- exposure prophylaxis.
P
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CJ- involved populations.32 33 Therefore, we postulate that 
we will be able to retain 80% of our study population for 
18- month follow- up.
This study will employ multiple processes to support 
participant retention over 18 months of data collection. 
These strategies operate at both the individual and 
organisational level. At the individual level, we will do 
same- day screening, enrolment and assessment when 
possible. Every 3 months, we will check- in with partici-
pants by phone, email, and field contact and will subse-
quently update locater information forms and send 
letters and postcards. Throughout the study, we will 
send personalised notes to participants (ie, birthdays, 
holidays), schedule appointments outside of their work 
hours and in the community that is most convenient for 
them, provide monetary incentives, establish a study Face-
book page, and conduct active case- finding for persons 
lost to follow- up (ie, internet searches, home visits). At 
the organisational level, we will develop a study logo and 
branding, conduct weekly automated prison and jail data-
base searches, and have regular team conference calls. At 
year one, we will have a retention training workshop and 
conduct study and site training.
Each site will tailor or add additional methods based 
on experience and resources and sites will continually 
communicate with each other to ensure adherence to 
all retention methods. Additionally, through engaging in 
automated prison and jail database searches, we will track 
participants in real time as they experience incident rein-
carceration. Individuals that become reincarcerated will 
remain in the study if they are able to attend scheduled 
study visits after incarceration.
Study exposures and outcomes
Our outcomes for aim 1 are PrEP knowledge and accept-
ability. PrEP knowledge will be assessed by asking partic-
ipants if they have prior knowledge of PrEP and PrEP 
acceptability will be assessed using the Willingness to Use 
PrEP scale.34 35 Our outcomes for aim 2 are PrEP initia-
tion and sustained use. PrEP initiation is a dichotomous 
measure defined as receiving/filling a prescription for 
PrEP as reported at the first follow- up assessment (at 
6 months). Sustained use is defined as self- report daily 
adherence assessed by the number of PrEP doses taken 
in the last 30 days. This measure of adherence will be 
collected at 6, 12 and 18 months follow- ups. Self- reported 
adherence will be supplemented by clinical chart abstrac-
tion. Secondary outcomes for aim 2 are HIV serocon-
version (~20 seroconversions are anticipated) as well as 
dichotomous and count measures of non- PrEP- related 
health service utilisation (eg, emergency department, 
other preventative care) and behaviours associated with 
high HIV risk. A combination of individual (eg, health-
care utilisation), social (eg, social support) and structural 
factors (eg, re- incarceration) serve as exposure variables 
of interest.
The study is using a sequential design in which aim 3 
builds on aims 1 and 2 to help elucidate patterns of PrEP 
use and multilevel factors that facilitate or act as barriers 
to PrEP knowledge, initiation, and sustained use. Specif-
ically, aim 3 includes qualitative interviews which are 
designed to illicit a rich descriptive narrative regarding 
the PrEP continuum of care. Example questions include 
‘Describe how concerned you are that other people know 
you are on (or might be considering) PrEP?” or “If we 
were going to create an intervention that would help 
support you in getting your PrEP prescriptions, getting to 
the clinic, and taking PrEP every day, what do you think 
would be helpful?’
Sample size calculations
Retention of participants is assumed to be 80% at each 
follow- up through 18 months (ie, 528 evaluable at each 
follow- up). A primary objective of Aims 1 and 2 is to 
estimate the probabilities of PrEP knowledge, accept-
ability, initiation and sustained use, overall and at each 
site. The anticipated proportions having these outcomes 
are unknown. Table 1 provides precision calculations for 
observed proportions ranging from 50% to 90%. Power 
to detect associations depends on the true probabilities 
of PrEP knowledge, acceptability, initiation and sustained 
use is shown in table 2.
For example, analysing the full cohort and a covariate 
with 50% prevalence, there will be sufficient power 
(>80%) to detect an OR of 2.0 or larger at a single time 
point for a reference group proportion (P) with the 
outcome event (eg, PrEP initiation) ranging from 20% 
to 80% (table 2 presents P: 50%–80%). For site- specific 
Table 1 Precision calculations for proportions with PreP knowledge, acceptability and initiation
Full cohort (528 evaluable) Site- specific (176 evaluable)
Proportion (95% CI) CI half- width Proportion (95% CI) CI half- width
0.5 (0.46 to 0.54) 0.043 0.5 (0.42 to 0.58) 0.076
0.6 (0.56 to 0.64) 0.043 0.6 (0.53 to 0.68) 0.075
0.7 (0.66 to 0.74) 0.040 0.7 (0.63 to 0.77) 0.070
0.8 (0.76 to 0.83) 0.035 0.8 (0.73 to 0.86) 0.061
0.9 (0.87 to 0.92) 0.027 0.9 (0.84 to 0.94) 0.048
Exact binomial 95% CIs are shown.
PrEP, pre- exposure prophylaxis.
P
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analyses, an OR of 3.5 or larger at a given time point will 
be detectible with >85% power for P ranging from 10% to 
70%. Longitudinal analyses incorporating measurements 
from baseline, 6, 12, and 18 months will have higher 
power that will be impacted by within- individual correla-
tions over time. Analyses of sustained PrEP use will be 
among the subsample who initiate PrEP and site- specific 
analyses of sustained PrEP will be descriptive.
Qualitative data collection
SPECS cohort participants will be categorised into the 
following three groups for each site: never initiated PrEP, 
initiated but did not sustain and initiated and sustained. 
Research randomiser ( www. randomizer. org) will be used 
to randomly select eight or nine individuals from each 
of the three groups to participate in the qualitative inter-
view. Enrollment will continue until data analysis reflects 
saturation, with 25 interviews anticipated at each study 
site and approximately an equal number of interviews of 
parolees who (1) never initiated PrEP, (2) initiated PrEP 
but did not sustain use and (3) initiated and sustained use 
of PrEP. Participants will receive US$40 for completing 
the interview. Interviews will take place in year 4 and 5 
so the qualitative sample will include those who had long 
term, sustained use of PrEP. In- depth qualitative inter-
views will last 60–90 min and will take place face- to- face, 
in a private room at a community- based venue convenient 
for the participant. All interviews will be digitally recorded 
and professionally transcribed. Team members who have 
training and expertise in qualitative research will conduct 
the interviews. Content of interviews will be guided by the 
conceptual framework, our research objectives, and find-
ings from the quantitative data collected via aims 1 and 2. 
However, we expect to explore the domains below:
1. Risk compensation. Example questions will include: 
(1) Has your HIV risk behaviour changed over time, 
recently, please explain? For instance, is there a period 
in the past when you were engaging in risky behaviour 
and then a time when you thought you definitely were 
not? Can you tell me about those times? (2) Do you 
think use of PrEP affected your risk engagement, why/
why not?
2. Knowledge, acceptability and experience related to 
PrEP initiation/sustained use. Example questions will 
include: (1) Can you tell me a little bit about your ex-
perience with PrEP (prompts for follow- up will include 
questions relevant to the PrEP clinic and provider, 
their experience accessing PrEP clinic visits and avail-
ability of PrEP in their community, etc); (2) When you 
think about making the decision to stay on PrEP or 
not take PrEP, what comes to mind as something that 
helped you make that decision?
3. The multilevel barriers/facilitators of PrEP initiation/
sustained use and suggestions for future PrEP interven-
tion components. Example questions will include: (1) 
Earlier I asked if anything you had been dealing with 
might be affecting your HIV risk behaviour, similarly, 
do you think any of the things you’ve been dealing 
with might have affected your PrEP use, why/why not?; 
(2) Were you ever concerned what other people would 
think if they knew you were on (or might be consider-
ing) PrEP? (3) If we were going to create an interven-
tion that would help support you in getting your PrEP 
prescriptions, getting to the clinic, and taking PrEP ev-
ery day, what do you think would be helpful?
4. Interest in new PrEP modalities. Example questions 
will include: (1) There are many different emerging 
models for how to get PrEP. Would you be interested in 
getting PrEP from a shot that you only had to get every 
few months, why/why not? (2) Would you be interest-
ed in getting your PrEP prescription in the mail, why/
why not? (3) Would you be interested in completing a 
self- HIV test at home every 3 months and mailing it to 
the clinic instead of having to have an in person visit, 
why/why not? (4) Which of these options would you 
most prefer?
Quantitative analyses
Data analysis will be guided by our conceptual framework, 
which postulates that PrEP knowledge, acceptability, 
initiation and sustained use are impacted by multilevel 
factors at the individual, social and structural levels. The 
multilevel nature of these factors will be considered when 
constructing analytic models. Quantitative analyses will 
be conducted using the full cohort of 660 participants 
and also evaluated within each site (n=220 per site) to 
elucidate state- specific outcomes. Both aims 1 and 2 will 
use a descriptive, bivariate and multivariable approach 
for analyses. Aim 1 multivariable analyses will use (1) 
generalised linear models (GLM) to estimate associa-
tions between independent variables (ie, exposures) and 
the outcomes of (A) PrEP knowledge and (b) average/
high PrEP acceptability. We will estimate model- based 
predicted probabilities of PrEP acceptability based on 
key independent variables (eg, sex, race/ethnicity, sexual 
identity, CJ history, MSM, IDU) to elucidate key subpopu-
lations where future interventions are needed to improve 
PrEP acceptability. Aim 2 will conduct multivariable anal-
yses using GLMs to analyse longitudinal data for sustained 
PrEP use, and will examine results at each follow- up time 
point. Generalised estimating equations with robust SE 
estimates36 37 will be used to estimate parameters of a 
GLM; a priori we will assume an exchangeable working 
Table 2 Power to detect association between an 
independent variable with 50% prevalence and PrEP 
outcomes (N=528 evaluable)
OR P=0.5 P=0.6 P=0.7 P=0.8
1.75 88.7 85.6 78.6 65.0
2.00 97.3 95.8 91.7 80.9
2.25 99.5 98.9 97 90.0
p=proportion with the outcome (eg, PrEP initiation) in the reference 
group.
PrEP, pre- exposure prophylaxis.
P
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correlation structure. Covariate associations with PrEP 
initiation, time- to- initiation and number of PrEP clinic 
appointments kept will also be analysed. We will esti-
mate associations between individual, social, and struc-
tural factors and time to initiation of PrEP, with proper 
handling of right- censored observations for those who do 
not initiate PrEP.38 39 While our primary outcome of PrEP 
initiation will be measured at 6- month follow- up, PrEP 
initiation can be examined at all follow- up time points. 
Additional secondary outcomes of interest include: HIV 
seroconversion (~20 seroconversions are anticipated), 
non- PrEP- related health service utilisation, reincarcera-
tion and substance use. Missing data will be an important 
consideration, and will be handled in multivariable 
analyses using a missing at random assumption, when 
deemed tenable, via application of multiple imputation 
or inverse probability of missingness weights.40–42 If data 
are suspected to be missing not at random, this will be 
described as a limitation.
Qualitative analyses
Aim 3 will qualitatively assess the multi- level factors that 
affect PrEP acceptability, initiation and sustained use 
to inform future intervention development. A general 
inductive approach guided by the conceptual framework 
and the research objectives will be used.43 A preliminary 
codebook will be developed after the first three transcripts 
from each category (eg, those who never started PrEP, 
those who initiated but did not sustain PrEP use, and 
those who sustained PrEP use) are complete. The coding 
scheme will be tested and two coders will code the text 
segments, compare coding and discuss and resolve areas 
of discrepancy, and then code another 20 text segments 
and percentage agreement will be calculated. Open 
coding will be done first followed by broad thematic anal-
ysis. Transcripts will be coded with axial codes, or more 
interpretive codes, that will be used in order to identify 
core concepts. In addition, memos and theory notes will 
be generated throughout the analysis.
Timeline
During the Fall of 2019, we will begin cohort recruitment 
and follow- up, which will continue through the Summer 
of 2022. Aim 1 analysis will take place in 2021–2022 
while aim 2 analysis will take place in 2021–2023. Aim 3 
protocol development and recruitment will take place in 
the second half of 2021 while aim 3 data collection and 
analysis will take place in 2022–2023. Dissemination of 
findings will take place in 2021–2023.
Patient and public involvement
No patients involved.
The coronavirus pandemic
Due to the coronavirus pandemic, we will adjust our 
recruitment and retention efforts. In March of 2020, 
in- person recruitment and retention will pause and tran-
sition to conduct all retention virtually through phone 
calls. For retention, we will send personalised mailers 
to enrolled participants, pay participants for contacting 
SPECS’ staff, and give participants a bonus for completing 
their retention visits within a week of when they were 
scheduled. We will also begin a coronavirus survey with an 
additional cash incentive for enrolled participants. With 
additional incentives, particpants will go from earning 
up to US$190 to earning up to US$265 for completing 
SPECS.
Recruitment will be paused beginning March 2020. 
When feasible, we will resume recruitment using chain 
referral, asking enrolled participants to refer up to five 
potentially eligible peers to us (ie, anyone placed on 
probation, postrelease supervision or parole in the past 
12 months). Enrolled participants will receive US$10 for 
each referral, regardless of if the referalls qualify for the 
study. Qualifying individuals will complete the baseline 
interview over the phone. Once it is safe to do so, we will 
return to in- person recruitment and retention.
ETHICS AND DISSEMINATION
While PrEP is highly effective at preventing HIV, it will 
be most effective if used by those for whom traditional 
approaches for HIV prevention have failed. HIV preva-
lence among CJ- involved populations remains five times 
that of the general population, yet little remains known 
about PrEP uptake among CJ- involved individuals and 
about facilitators and challenges to PrEP uptake and 
sustained use.12 By adopting a conceptual framework that 
recognises PrEP decisions are made within individual, 
social and structural levels, SPECS is designed to respond 
to and close the knowledge gap regarding PrEP among 
people involved in the CJ system.
The SPECS cohort will establish a platform to support 
future research related to PrEP outcomes among 
parolees. We suspect that future research could include: 
(1) Comparison of PrEP- related outcomes among cohort 
members who do and do not become re- incarcerated 
during the study period; (2) Spatial epidemiological 
analyses using geographic information derived from 
offender databases and collected from cohort partici-
pants and (3) Study of the possible effect of Medicaid 
expansion in KY and non- expansion of Medicaid in FL 
and NC. Similarly, we can compare across states for other 
outcomes. In terms of future interventions, we anticipate 
the results of SPECS will highlight specific needs that 
should be addressed for certain subgroups. For example, 
our results could indicate that some subgroups might 
be more likely to initiate PrEP but less likely to engage 
in sustained use—identifying a key intervention time 
point in the PrEP care cascade. We could also find that 
certain groups experience very specific barriers to PrEP 
use postrelease, identifying the need to provide tailored 
support. Therefore, SPECS will lay the groundwork for 
future randomised clinical trials to evaluate the efficacy 
of multiple PrEP- related interventions that are tailored 
for CJ- involved individuals.
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Ethical concerns
A primary ethical concern is that we are collecting highly 
sensitive, personal information from a population that 
often experiences stigma and discrimination and is at high 
risk for recidivism. Specifically, we collect information on 
activities that are illegal, notably illicit drug use. Recog-
nising this, the collection of identifiable information will 
be minimised to the greatest extent possible. Extensive 
efforts will be dedicated to protecting the confidentiality 
and privacy of study participants. Specifically, all data will 
be stored in a deidentified format and only accessed by 
the study team. Participants will be thoroughly briefed 
on these protections as part of the consent process. The 
study’s protocol and procedures have been reviewed 
and approved by the institutional review boards at the 
University of North Carolina at Chapel Hill (18–2466). 
In addition, participants are protected under a federal 
Certificate of Confidentiality.
Additionally, the baseline assessment may take place 
in private rooms in probation and parole offices, or a 
community venue of the participant’s choice (eg, private 
room at the university or a community- based organi-
sation). The baseline assessment at the probation and 
parole office is often ideal, as we can recruit from the 
waiting room and each site has been given a private space 
to screen and conduct the baseline assessment. However, 
we acknowledge that it will be important to reassure 
participants, during the consent procedure that their 
answers will be confidential, and issues discussed will in 
no way impact their CJ status, nor ability to obtain or be 
referred to medical care or social services. In addition, 
we will not share the purpose of the study with individual 
probation or parole officers. Instead, this study will be 
referred to broadly as a ‘health study’.
Methodological limits and concerns
This study has methodological limitations that merit 
further discussion. First, it is possible that we will not 
recruit the number of participants needed at each site. 
If this is the case, we will expand recruitment to addi-
tional district offices in each site location. In addition, 
if needed, we will expand to recruit from community- 
based organisations. Similarly, it is possible that we retain 
fewer than 80% of participants. If this is the case, we will 
redirect the duties of one research staff member at each 
site to focus solely on retention efforts. If retention is 
below 80%, we will also increase the dollar amount of the 
follow- up incentives. Second, while we assume a sizeable 
portion of our cohort will initiate and sustain PrEP, the 
proportion may be low. As a part of our power calcula-
tions, we have estimated a wide range of possible outcome 
events. Therefore, even if the number of individuals who 
initiate and sustain PrEP is low, we should have the power 
to perform our planned analyses. In addition, if we find 
that few people initiate and sustain PrEP, we will reorient 
aim 3 to focus on the reasons for non- initiation or unsus-
tained use. Third, while the most robust PrEP adherence 
measure would be to measure drug concentration in dried 
blood spots (DBS), this is very expensive and typically not 
feasible for real- world PrEP observational studies. We 
are, therefore, assessing adherence using self- reported 
number of missed doses in the past 30 days. Recall over 
30- day periods is commonly used as a measure of adher-
ence, and these measures have demonstrated reliability 
when compared with objective measures of adherence. In 
addition, this adherence measure has been found to be 
highly consistent with drug concentrations found using 
DBS analysis of PrEP.44 Lastly, cohort studies may bias, 
due to recall and social desirability bias of self- reported 
measures, in- selection bias due to HIV- related stigma, 
out- selection bias due to attrition, and data missing not 
at random.
CONCLUSIONS
There are many reasons to study the health of CJ- involved 
populations in the US South, specific to and beyond HIV 
prevention. The CJ system and HIV continue to dispro-
portionally affect POC and vulnerable populations, and 
these effects are strongest in the US South. While SPECS 
aims to contribute to the growing body of literature on 
PrEP uptake and retention among this population, it 
also aims to address inequities in research, specifically 
the paucity of data that can be used to improve the lives 
and health of CJ- involved populations at risk of HIV. 
This study’s dataset will provide the potential to answer 
related questions to reduce the risk of HIV and ultimately 
improve the lives of these individuals.
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